2016
Controversies in the Treatment of Women with ST-Segment Elevation Myocardial Infarction
Ng VG, Lansky AJ. Controversies in the Treatment of Women with ST-Segment Elevation Myocardial Infarction. Interventional Cardiology Clinics 2016, 5: 523-532. PMID: 28582000, DOI: 10.1016/j.iccl.2016.06.014.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionMyocardial infarctionWorse outcomesOutcomes of womenCoronary artery diseaseCause of deathTreatment of womenReperfusion therapyAggressive treatmentArtery diseaseLate therapyTreatment optionsDisease presentationOutcome disparitiesPlaque developmentInfarctionTherapyWomenYoung menOutcomesMenTreatmentPathophysiologyDisease
2012
Interventions for ST Elevation Myocardial Infarction in Women
Ng VG, Lansky AJ. Interventions for ST Elevation Myocardial Infarction in Women. Interventional Cardiology Clinics 2012, 1: 453-465. PMID: 28581963, DOI: 10.1016/j.iccl.2012.06.004.Peer-Reviewed Original ResearchST-segment elevation myocardial infarctionElevation myocardial infarctionReperfusion therapyMyocardial infarctionST-elevation myocardial infarctionOutcomes of patientsMinority of patientsOutcomes of womenCoronary revascularization techniquesCause of deathRevascularization techniquesSupportive careTreatment optionsCardiovascular diseaseEquivalent outcomesTherapyWomenMultiple studiesOutcomesInfarctionPatientsMenThrombolyticsDiseaseTrials
2010
When Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials
Brodie BR, Gersh BJ, Stuckey T, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Grines CL, Cox D, Parise H, Prasad A, Lansky AJ, Mehran R, Stone GW. When Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials. Journal Of The American College Of Cardiology 2010, 56: 407-413. PMID: 20650362, DOI: 10.1016/j.jacc.2010.04.020.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionLower mortality rateHigh-risk patientsPercutaneous coronary interventionMortality rateEarly presentationCoronary interventionClinical riskST-segment elevation myocardial infarctionSimilar relative risk reductionsHORIZONS-AMI trialElevation myocardial infarctionRelative risk reductionNon-percutaneous coronary intervention hospitalsMortality rate reductionImpact of doorCADILLAC trialHORIZONS-AMIAntithrombotic therapyReperfusion therapyBalloon timeIntervention hospitalsAbsolute benefitLate presentationMyocardial infarction
2009
Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial
Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. JACC Cardiovascular Interventions 2009, 2: 624-632. PMID: 19628185, DOI: 10.1016/j.jcin.2009.05.004.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAge FactorsAgedAnemiaAngioplasty, Balloon, CoronaryAntibodies, MonoclonalErythrocyte TransfusionFemaleHeart DiseasesHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRadiographyRecurrenceRisk AssessmentRisk FactorsSeverity of Illness IndexSex FactorsStrokeTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIRBC transfusionCADILLAC trialClinical outcomesComposite major adverse cardiac eventsAcute Myocardial Infarction AnalysisMajor adverse cardiac eventsCoronary artery bypass surgeryRed blood cell transfusionMechanical reperfusion therapyAdverse cardiac eventsArtery bypass surgeryBlood cell transfusionTriple vessel diseasePercutaneous coronary interventionBaseline anemiaMajor bleedingTransfusion propensityCell transfusionIndex hospitalizationMultivariable adjustmentPrimary angioplastyReperfusion therapy
2005
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction
Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tcheng JE, Mehran R, Lansky AJ, Kandzari DE, Grines CL, Stone GW. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. European Heart Journal 2005, 26: 667-674. PMID: 15734768, DOI: 10.1093/eurheartj/ehi167.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIPercutaneous coronary interventionST-segment recoveryMyocardial blushCoronary interventionMultivariable analysisPrognostic utilityMyocardial infarctionGreater prognostic utilityStrongest prognostic variableYear clinical outcomesIncremental prognostic informationCADILLAC trialReperfusion therapyReperfusion successClinical outcomesGrade 2/3Independent correlatesMicrocirculatory integrityPrognostic informationUnivariate analysisPoor survivalCumulative rate
2004
Impact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction
Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, Lansky AJ, Stone GW. Impact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 43: 1780-1787. PMID: 15145099, DOI: 10.1016/j.jacc.2003.10.068.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIBeta-blocker useMyocardial recoveryMyocardial infarctionLate Angioplasty Complications (CADILLAC) trialOral beta-blocker medicationOral beta-blocker useLeft ventricular ejection fractionIntravenous beta blockadeMechanical reperfusion therapyAbsence of contraindicationsBeta-blocker therapyBeta-blocker medicationBeta-blocker administrationPercutaneous coronary interventionVentricular ejection fractionBeta blockadeControlled AbciximabPrimary angioplastyReperfusion therapyComplications TrialCoronary interventionSurvival benefitImportance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M, Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, Stone GW. Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. Journal Of The American College Of Cardiology 2004, 43: 1368-1374. PMID: 15093869, DOI: 10.1016/j.jacc.2003.11.046.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMitral Valve InsufficiencyMyocardial InfarctionPlatelet Aggregation InhibitorsPrognosisProspective StudiesSeverity of Illness IndexStentsSurvival AnalysisTreatment OutcomeConceptsAcute myocardial infarctionLeft ventricular ejection fractionMechanical reperfusion therapySevere mitral regurgitationMitral regurgitationIndex procedureReperfusion therapyIndependent predictorsMyocardial infarctionLate Angioplasty Complications (CADILLAC) trialPresence of MRHigher Killip classMechanical reperfusion strategiesNon-shock patientsHigh-risk patientsLong-term mortalityTriple vessel diseasePercutaneous coronary interventionVentricular ejection fractionMild mitral regurgitationControlled AbciximabKillip classReperfusion strategyComplications TrialCoronary intervention
2001
Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction
Stone G, Cox D, Garcia E, Brodie B, Morice M, Griffin J, Mattos L, Lansky A, O’Neill W, Grines C. Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction. Circulation 2001, 104: 636-641. PMID: 11489767, DOI: 10.1161/hc3101.093701.Peer-Reviewed Original ResearchConceptsTIMI 3 flowAcute myocardial infarctionInitial TIMI 3 flowMyocardial infarctionPrimary PTCAEarly reperfusionHeart failureIndependent determinantsNew-onset heart failurePostprocedural TIMI 3 flowTIMI 3 flow ratesMechanical reperfusion therapyTIMI 0/1 flowTIMI 2 flowProspective randomized trialsShorter hospital stayVentricular ejection fractionInitial angiographyAngiographic evidenceHospital stayLytic therapyReperfusion therapyVentricular failureSpontaneous reperfusionEarly administration